Author(s): Tsou, MF (Tsou, Mei-Fen); Peng, CT (Peng, Ching-Tien); Shih, MC (Shih, Mu- Chin); Yang, JS (Yang, Jai-Sing); Lu, CC (Lu, Chi-Cheng); Chiang, JH (Chiang, Jo-Hua); Wu, CL (Wu, Chang-Lin); Lin, JP (Lin, Jing-Pin); Lo, C (Lo, Chyi); Fan, MJ (Fan, Ming-Jen); Chung, JG (Chung, Jing-Gung)
Title: Benzyl isothiocyanate inhibits murine WEHI-3 leukemia cells in vitro and promotes phagocytosis in BALB/c mice in vivo
Source: LEUKEMIA RESEARCH, 33 (11): 1505-1511 NOV 2009 Language: English
Document Type: Article
Author Keywords: Benzyl isothiocyanate (BITC); WEHI-3 leukemia cells; BALB/c mice;
Immune response; Cytotoxicity
KeyWords Plus: MITOCHONDRIAL DEATH PATHWAY; ACTIVATED PROTEIN-KINASES;
CYCLE ARREST; CANCER-RISK; CARCINOMA-CELLS; CRUDE EXTRACTS; BREAST- CANCER; A/J MICE; KAPPA-B; APOPTOSIS
Abstract: Many evidences have shown that dietary intake of cruciferous vegetables could protect against the risk of various types of malignancies. Benzyl isothiocyanate (BITC), one of the compounds from cruciferous vegetables, had shown induced cell cycle arrest and
apoptosis in cancer cells. However, there is no available information to address that BITC affects murine leukemia cells in vitro and in vivo. Here, we investigated in vitro effects of BITC on murine leukemia WEHI-3 cells. BITC decreased the percentage of viable cells via GO/G1 arrest and apoptosis in WEHI-3 cells. BITC induced apoptosis through the dysfunction of mitochondria (decreased the levels of mitochondria membrane potential) and activation of caspase-3. Then we investigated in vivo effects of BITC on murine leukemia WEHI-3 cells and the results indicated that BITC decreased the weights of liver and spleen and it also
decreased the percentage of CD11b and Mac-3 markers, indicating that the differentiation of the precursor of macrophage and B cells was inhibited. BITC promoted the activity of
macrophage phagocytosis in cells which are isolated from PBMC and peritoneal (i.p.). Taken together, BITC can affect WEHI-3 cells in vitro and in vivo. Crown Copyright (C) 2009 Published by Elsevier Ltd. All rights reserved.
Addresses: [Wu, Chang-Lin; Chung, Jing-Gung] China Med Univ, Dept Biol Sci & Technol, Taichung 404, Taiwan; [Tsou, Mei-Fen; Peng, Ching-Tien; Shih, Mu-Chin] China Med Univ Hosp, Dept Lab Med, Taichung 404, Taiwan; [Peng, Ching-Tien] China Med Univ Hosp, Dept Pediat & Hematooncol & Med, Taichung 404, Taiwan; [Peng, Ching-Tien; Fan, Ming-Jen;
Chung, Jing-Gung] Asia Univ, Dept Biotechnol, Taichung 413, Taiwan; [Yang, Jai-Sing] China Med Univ, Dept Pharmacol, Taichung 404, Taiwan; [Lu, Chi-Cheng; Chiang, Jo-Hua] Natl Chung Hsing Univ, Dept Life Sci, Taichung 402, Taiwan; [Lin, Jing-Pin] China Med Univ, Sch Chinese Med, Taichung 404, Taiwan; [Lo, Chyi] China Med Univ, Sch Nursing, Taichung 404,
Taiwan; [Lo, Chyi] China Med Univ, Grad Inst Chinese Med Sci, Taichung 404, Taiwan Reprint Address: Chung, JG, China Med Univ, Dept Biol Sci & Technol, Taichung 404, Taiwan.
E-mail Address: jgchung@mail.cmu.edu.tw Funding Acknowledgement:
Funding Agency Grant Number
China Medical University Hospital (CMUH), Taichung, Taiwan DMR-97-111
This study was supported by grant DMR-97-111 from the China Medical University Hospital (CMUH), Taichung, Taiwan.
Cited References: ABE J, 1987, FEBS LETT, V226, P58.
AMBROSONE CB, 2004, J NUTR, V134, P1134.
COHEN JH, 2000, J NATL CANCER I, V92, P61.
CONAWAY CC, 2002, CURR DRUG METAB, V3, P233.
FOWKE JH, 2003, CANCER RES, V63, P3980.
HE Q, 2001, LEUKEMIA RES, V25, P455.
HSU MH, 2007, EUR J PHARMACOL, V559, P14, DOI 10.1016/j.ejphar.2006.12.001.
HSU SC, 2007, ANTICANCER RES, V27, P2377.
HSU SC, 2008, ANTICANCER RES, V28, P1045.
HUANG YT, 2002, INT J CANCER, V99, P505.
JENSEN CD, 2004, CANCER CAUSE CONTROL, V15, P559.
LAKEN MR, 2000, FLOW CYTOMETRY PRACT, P61.
LIN JG, 2006, J UROLOGY, V175, P343, DOI 10.1016/S0022-5347(05)00005-4.
LIN JM, 1993, CANCER LETT, V74, P151.
LIN ML, 2007, ANTICANCER RES, V27, P3313.
LU KW, 2008, ANTICANCER RES, V28, P1093.
MIYOSHI N, 2004, CANCER RES, V64, P2134.
NAKAMURA Y, 2002, J BIOL CHEM, V277, P8492.
RICHARDS J, 2006, P AM ASSOC CANC RES, P47.
SATCHELL DP, 1996, J STEROID BIOCHEM, V57, P117.
SRIVASTAVA SK, 2004, CARCINOGENESIS, V25, P1701, DOI 10.1093/carcin/bgh179.
SU CC, 2008, IN VIVO, V22, P63.
SUGIE S, 1993, JPN J CANCER RES, V84, P865.
TSENG E, 2004, EXP BIOL MED, V229, P835.
VERHOEVEN DTH, 1996, CANCER EPIDEM BIOMAR, V5, P733.
VISANJI JM, 2004, J NUTR, V134, P3121.
WARNER NL, 1969, J NATL CANCER I, V43, P963.
WATTENBERG LW, 1977, J NATL CANCER I, V58, P395.
WATTENBERG LW, 1981, CANCER RES, V41, P2991.
WATTENBERG LW, 1987, CARCINOGENESIS, V8, P1971.
WIETRZYK J, 2007, ANTI-CANCER DRUG, V18, P447.
YANG JS, 2006, ANTICANCER RES, V26, P219.
YANG YM, 2002, CANCER RES, V62, P2.
ZUCKER RM, 1989, TOXICOLOGY, V58, P107.
Cited Reference Count: 34 Times Cited: 2
Publisher: PERGAMON-ELSEVIER SCIENCE LTD
Publisher Address: THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
ISSN: 0145-2126
DOI: 10.1016/j.ieukres.2009.01.030 29-char Source Abbrev.: LEUK RES ISO Source Abbrev.: Leuk. Res.
Source Item Page Count: 7
Subject Category: Oncology; Hematology ISI Document Delivery No.: 495DM
